Atlas Venture Life Science Advisors, LLC
Annual return '25
+18.0%
SPY '25
+17.7%
Alpha
+0.3ptsvs SPY
Invested
$790M
Holdings
6
Trades YTD
0
Performance · Fund vs SPY
Cumulative return · quarterly snapshotsCoverage 93%. 4 quarters of 2025 measured against SPY adj-close benchmark.
Top holdings · current snapshot
Source: 13F-HR01
$KYMR
Kymera Therapeutics, Inc.
Q4 2025: Exited (was 4.90M shares)
48.3%
02
$DYN
Dyne Therapeutics, Inc.
Q4 2025: Exited (was 9.13M shares)
21.0%
03
$SION
Sionna Therapeutics, Inc.
Q4 2025: Exited (was 3.62M shares)
15.2%
04
$IRON
Disc Medicine, Inc.
Q4 2025: Exited (was 2.14M shares)
12.3%
05
$QTTB
Q32 Bio, Inc.
Q4 2025: Exited (was 2.09M shares)
1.7%
06
$KRRO
Korro Bio, Inc.
Q4 2025: Exited (was 1.14M shares)
1.6%
Recent trades · Last 90 days
No Form 4 / 13D / 13G trade events on file in the recent window. 13F filers report position snapshots quarterly rather than per-trade events, so this section is most useful for managers who also file Form 4 or 13D/G.
Convergence · Pattern Engine ships in v1.1
30-day windowIn development
Convergence participation lands with the Pattern Engine.
Once the Pattern Engine ships, this section will list every active convergence event this fund is named in — with the other named funds, the Congress members on the same name, and combined position size.
Source data: SEC EDGAR · 13F-HR filings · Performance through 2025-12-31 · Last refreshed 08:12 UTC.